Melanoma Clinical Trial Tracker — Stay Current on Immuno-Oncology Innovation

Why melanoma trial monitoring matters

Melanoma has been the proving ground for immuno-oncology since the approval of ipilimumab in 2011. The therapeutic landscape continues to evolve rapidly, with new checkpoint inhibitor combinations, cell therapies, and targeted agents entering clinical development at an accelerating pace.

With over 400 active melanoma trials on ClinicalTrials.gov, the monitoring challenge is significant for pharma BD teams, biotech investors, and dermatologic oncology researchers. Key signals to track:

• Novel checkpoint inhibitor combinations (anti-LAG-3, anti-TIGIT, anti-TIM-3 paired with PD-1)
• TIL (tumor-infiltrating lymphocyte) therapy programs following lifileucel approval
• Neoadjuvant/adjuvant immunotherapy trials — a rapidly growing area
• BRAF/MEK inhibitor next-generation combinations
• mRNA-based personalized cancer vaccines (e.g., mRNA-4157/V940 and competitors)
• Trials in uveal melanoma, mucosal melanoma, and acral melanoma — underserved subtypes with distinct biology

What we monitor for melanoma

Our pipeline pulls directly from the ClinicalTrials.gov API every day. For a melanoma watch profile, you can configure:

• Condition keywords: "melanoma", "metastatic melanoma", "uveal melanoma", "mucosal melanoma", "BRAF V600E", "BRAF mutant melanoma"
• Phase filter: Phase 1 only, Phase 2/3, or all phases
• Sponsor filter: Industry-sponsored only (for competitive intelligence) or all sponsors
• Status filter: Recruiting only, all active studies, or any status

The melanoma treatment landscape in 2026

Next-generation immunotherapy combinations

The success of nivolumab + relatlimab (Opdualag) validated the dual checkpoint approach in melanoma. Now, dozens of programs are testing combinations involving LAG-3, TIGIT, TIM-3, and other immune checkpoints. Tracking new combination trials gives competitive intelligence teams early visibility into which targets and combinations are being prioritized by pharma companies.

Cell therapy beyond CAR-T

TIL therapy — using a patient's own tumor-infiltrating lymphocytes — has emerged as a distinct cell therapy modality in solid tumors. Following the approval of lifileucel (Amtagvi), multiple competitors are developing next-generation TIL products with shorter manufacturing times, enhanced potency, and combination approaches.

Personalized cancer vaccines

mRNA-based neoantigen vaccines represent one of the most anticipated advances in melanoma. The mRNA-4157/V940 + pembrolizumab combination has generated significant interest, and competitor programs are rapidly entering clinical development. Monitoring vaccine trial starts is essential for companies positioning in this space.

Neoadjuvant immunotherapy

Pre-surgical immunotherapy has shown remarkable pathological complete response rates in resectable melanoma. This paradigm shift is driving a wave of neoadjuvant trial registrations that could reshape the treatment algorithm for early-stage disease.

Who uses melanoma trial monitoring

Pharma and biotech companies

Companies with immuno-oncology programs track melanoma trial activity across the industry. Melanoma is often the first indication for novel immunotherapy mechanisms, making it a bellwether for broader I-O strategy decisions.

Oncology-focused investors

Investors monitor melanoma trial registrations as early signals for immunotherapy platform value. A new Phase 2 combination trial can signal a company's clinical development strategy months before any public announcement.

Academic researchers

Melanoma researchers at academic medical centers track new trial registrations to identify collaboration opportunities, understand the competitive landscape for their own investigator-initiated trials, and stay current on emerging mechanisms.

Frequently asked questions

How current is the melanoma trial data?

Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest.

Can I track melanoma subtypes separately?

Yes. On the Pro plan ($129/month), you can create up to 5 search profiles. You might have one profile for uveal melanoma, another for BRAF-mutant trials, and another for all Phase 3 immunotherapy combinations.

Does this cover international melanoma trials?

ClinicalTrials.gov includes trials conducted internationally, so yes — international melanoma trials registered on ClinicalTrials.gov are included. This covers most major industry-sponsored programs worldwide, particularly those with US sites.

How is this different from ClinicalTrials.gov alerts?

ClinicalTrials.gov offers basic RSS-style alerts without phase filtering, sponsor type filtering, or organized digest formatting. We provide filtered, labeled, and organized alerts — the intelligence layer on top of the raw registry data.